Preparing for European market launch

June 19, 2006

Ventracor Limited (ASX: VCR) today announced the first patient has been implanted with the VentrAssist in a new study designed to build on clinical momentum from the CE Mark Trial and prepare for European market launch.

The BRACE study (Baseline Results And Cost Effectiveness) will add to the body of evidence for the performance of the VentrAssist left ventricular assist device (LVAD) in up to 10 new centres in Europe. The new centres are in addition to the current Australian, NZ and European sites.

The BRACE study is a key component of Ventracor's commercialisation strategy to rapidly grow revenues after the anticipated CE Mark approval in early 2007.

The cost effectiveness results of the BRACE study will also be used to help obtain or increase reimbursement in key European markets.

After approval by the Regional Hospital Ethics Committee in Oslo, Norway, the first patient in the BRACE study, a 16 year-old girl was implanted last week.

Principal Investigator Dr Arnt Fiane at Rikshopitalet - Radiumhospitalet Medical Centre said: "We are excited about participating in the BRACE study for this potentially world-leading life-saving technology." Dr. Fiane added the patient was making a satisfactory recovery.

Ventracor Limited Chief Operating Officer Peter Crosby said: "We are very conscious that regulatory approval does not immediately equate to market acceptance.

"The BRACE study builds on the CE Mark Trial to expand clinical knowledge and understanding of the VentrAssist."

"By the time the VentrAssist receives CE mark approval later this year, we expect to have many more centres implanting the VentrAssist under the BRACE protocol and we can rapidly move to grow revenues from this established customer base.

"There have now been more VentrAssist third generation (3G) centrifugal LVADs implanted than all third generation centrifugal pumps from all our competitors combined," Mr Crosby said.
-end-
The BRACE study protocol was developed with Ventracor's global clinical investigators, statistical consultants and international Scientific Advisory Board. It has a similar inclusion and exclusion criteria to the successful CE Mark Trial and will gather data on long-term and short-term patient outcomes.

About Ventracor

Ventracor is a global medical device company which has developed a blood pump, the VentrAssist left ventricular assist device (LVAD) for patients in heart failure. Ventracor plans to bring the VentrAssist to the global market.

For further information, please contact: Andrew Geddes Manager, Investor Relations Ventracor Limited + 61 2 9406 3086

Research Australia

Related Approval Articles from Brightsurf:

COVID-19 shapes political approval ratings
During the early days of the pandemic, COVID-19 created a rally effect around political leaders, according to a large-scale study published Sept.

Improving FDA's COVID-19 vaccine authorization and approval process
On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use of hydroxychloroquine for the treatment of COVID-19, and on June 15, the agency revoked this authorization.

Clinical practice guideline approval process introduces potential conflicts of interest
A new study of the approval processes used by the 43 medical-specialty-society members of the Council of Medical Specialty Societies in the US to create evidence-based guidelines finds that most use an approval procedure that has the potential to undermine editorial independence of the guideline development committee.

Examining changes to FDA approval, regulation of pharmaceuticals over 4 decades
Publicly available and Food and Drug Administration (FDA) data were used in this observational study to describe the number and types of prescription drugs approved from 1983 to 2018 and how the approval process and regulation of drugs changed during this period.

One-third of pre-approved prescription drugs have not completed the FDA approval process
The Food and Drug Administration's (FDA) Accelerated Approval Program was created in 1992 to significantly accelerate the ability to bring certain new drugs to market.

Lower approval rates evidence of discrimination for same-sex borrowers
Mortgage lenders are less likely to approve loans for same-sex couples.

Leopoldina-Experts call for stricter approval procedures for plant protection products
A number of chemical plant protection products, also known as pesticides, show harmful effects on ecosystems and biodiversity in their current use.

New cancer immunotherapy drugs rapidly reach patients after approval
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study.

Less than half of patients prescribed new cholesterol drug receive insurance approval
In the largest study of its kind, less than half of patients prescribed the new class of cholesterol drugs, PCSK9 inhibitors, received insurance approval even if patients had atherosclerotic cardiovascular disease (plaque build-up of the arteries) or markedly elevated bad cholesterol.

Identifying the mechanism for a new class of antiviral drugs could hasten their approval
New research shows that a new class of antiviral drugs works by causing the virus' replication machinery to pause and backtrack, preventing the virus from efficiently replicating.

Read More: Approval News and Approval Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.